$CGTX

2 theses

bullish 100%neutral 0%bearish 0%

Avg return (1y)

—

Win rate (1y)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 17, 4:30 PM ET

$CGTXr/pennystocksStock Infobullish

u/Asleep-Procedure-131 · 105d agono track record yet

Long 36,300 shares of CGTX

How come no one is talking about CGTX?

CGTX announced phase 3 trial data with multiple near-term catalysts lined up in June, including the H.C. Wainwright Summit, Annual Shareholder Meeting, and FDA Written Minutes on June 19-20, which the author identifies as the primary catalyst. The phase 3 design is public and 3,000 institutional investors have been briefed, positioning the stock for potential upside as these catalysts approach.

At post $1.36Now $1.06-22.1% since postedas of Sep 17, 4:30 PM ET

1d-5.1%

3d-5.1%

1w-11.8%

1m-14.0%

3m-22.8%

6m—

1y—

original post →

$CGTXr/pennystocksDDbullish

u/footballman25 · 371d agono track record yet

Long CGTX

$CGTX the newest update— I am pounding the table

The author believes CGTX's stock has been oversold due to unfounded BTD denial rumors. With positive Phase 2 data showing pTau reversals, a fresh $30M capital raise securing Phase 3 runway, and a potential BTD approval catalyst in an unmet LBD market, the stock at $2 range offers a compelling buying opportunity before upcoming catalysts materialize.

Now $1.06as of Sep 17, 4:30 PM ET

original post →

End of results.